Nutex Health Inc. (NUTX) stock
NUTXNasdaqServices-Business Services, NECFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/3072% below fair value
$174.51+4.81 (+2.83%)
Close on Nov 17, 2026Market cap $1.20BP/E 6.9Yield –
Nutex Health r&d expenses
Research and development expenses are spending on new products and technology.
Nutex Health's R&D Expenses for the twelve months ending Mar 31, 2022 was $282.91K, down 45.5% year over year. For fiscal 2021 it was $285.88K, down 48.7% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $285.88K | -48.7% |
| FY2020 | Dec 31, 2020 | $557.26K | -27.5% |
| FY2019 | Dec 31, 2019 | $768.10K | +40.9% |
| FY2018 | Dec 31, 2018 | $545.22K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2022 | Mar 31, 2022 | $73.75K | -3.9% |
| Q4 FY2021 | Dec 31, 2021 | $77.27K | +42.3% |
| Q3 FY2021 | Sep 30, 2021 | $72.27K | -2.1% |
| Q2 FY2021 | Jun 30, 2021 | $59.63K | -81.0% |
| Q1 FY2021 | Mar 31, 2021 | $76.72K | -33.2% |
| Q4 FY2020 | Dec 31, 2020 | $54.30K | -72.4% |
| Q3 FY2020 | Sep 30, 2020 | $73.83K | -31.5% |
| Q2 FY2020 | Jun 30, 2020 | $314.26K | +11.3% |
| Q1 FY2020 | Mar 31, 2020 | $114.88K | -36.6% |
| Q4 FY2019 | Dec 31, 2019 | $196.63K | – |
| Q3 FY2019 | Sep 30, 2019 | $107.76K | – |
| Q2 FY2019 | Jun 30, 2019 | $282.46K | – |
| Q1 FY2019 | Mar 31, 2019 | $181.25K | – |
See a number that looks wrong?